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Results: Among 518 liver biopsies, the most frequent histological
ﬁnding was Mild Chronic Hepatitis (57.1%, n=296) followed by
moderate Chronic Hepatitis (41.5%, n=215) and Severe Chronic
Hepatitis was found in 7 patients (1.4%).
87.5% patients had grade 0-8 (mild chronic inﬂammation) accord-
ing to HAI scoring system. 56.6% (n=293) patients had no ﬁbrosis
(stage 0), 42.8% (n=222) had some degree of ﬁbrosis (stage 1-5)
and 0.6% n=3 had cirrhosis (stage 6) on liver biopsy according to
HAI scoring system.
Among those with normal ALT 63% had mild inﬂammation and 37%
had moderate to severe inﬂammation. About 54.5% of those with
high ALT also had mild inﬂammation and 45.5% had moderate to
severe inﬂammation.
Conclusion: Thus there was no statistically signiﬁcant relation-
ship between ALT levels and the severity of Inﬂammation on Liver
Biopsy (p value of 0.085)
PP-134 HCV F protein, a protein correlating with HCV
chronic infection
Jing Kong*, Xiaozhao Deng, Zhongchan Wang, Yun Zhang,
Chunli Chu. Huadong Research Institute for Medicine and
Biotechniques
Objectives: Hepatitis C virus (HCV) produces a novel protein,
known as F protein. F protein is encoded by an open reading
frame (ORF) that overlaps the core gene in the +1 frame (core
+1 ORF). In this study, we attempt to understand the biological
functions of the F protein in the pathogenesis of HCV infection.
Methods: HCV F protein, a +1 frameshifting at codon 42 followed
by a rephasing in the normal open reading frame at stop codon
144, from the genotype 1b are expressed in E. coli. Proteins from
E. coli lysates transformed with pGEX-F and the corresponding
empty vector (pGEX-4T-2) were subjected to 10% SDS-PAGE and
detected using Western blotting. The presence of antibodies
speciﬁc for the novel F protein was evaluated in the serum of
patients with an indirect ELISA.
Results: E. coli BL21 (DE3) cells harboring the plasmids were
harvested, and lyzed in SDS sample buffer and examined for the
production of aimed protein about 43kD on SDS-PAGE.
Results: of indirect ELISA carried out on 120 serum samples
from 28 acute HCV patients, 62 chronic HCV patients, 30 hepatic
cirrhosis, and 10 healthy samples. Sera of 54% (15/28) of the HCV
acute patients reacted with F protein, compared to 37 of the 62
(60%) chronic patients, and 20 of 30 (67%) liver cirrhosis infected
with HCV, and this association reached statistical signiﬁcance.
Conclusion: F protein may intimately linked to the molecular
pathogenesis in HCV-infected individuals.
PP-135 Up-regulation of HCV p7 on ASGPR1 gene
promoter
Jiang Guo*. Institute of Infectious Diseases, Beijing Ditan
Hospital, Beijing, China
Background: To investigate the transregulating effect of HCV p7
on ASGPR1 gene promoter.
Methods: Polymerase chain reaction (PCR) technique was em-
ployed to amplify the coding sequence of ASGPR1 promoter from
HepG2 genomic DNA, and the product was subcloned into pCAT3-
Basic by Kpn I and Bgl II, named pCAT3-ASGPR1p. pCAT3-ASGPR1p
was transfected into the hepatoblastoma cell line HepG2, then
cotransfected with pcDNA3.1(–)-HCV p7 by FuGENE 6 transfec-
tion reagents. The HepG2 cells transfected with pCAT3-Basic was
used as negative control. The activity of CAT in HepG2 cells
transfected was detected by a ELISA kit after 48 hours, which
reﬂected the transregulating function of pcDNA3.1(–)-HCV p7 to
ASGPR1 gene promoter.
Results: The report vector pCAT3-ASGPR1p has been constructed
and had been conﬁrmed by restriction enzyme digestion and
sequencing. The expression of CAT in HepG2 cells co-transfected
with pCAT3-ASGPR1p and pcDNA3.1(–)-HCV p7 was 7.7 times
as higher as that of pCAT3-Basic,and 2.4 as higher as that of
pCAT3-ASGPR1p.
Conclusions: HCV p7 can transregulate ASGPR1 promoter, and so
can up-regulate the expression of ASGPR1 gene.
PP-136 Liver steatosis and treatment of hepatitis C viral
infection
Gulnara Aghayeva*, Ali Hidayatov. Internal Diseases
Department, Azerbaijan State Medical University
Objectives: There has been increasing evidence indicating
metabolic disturbances in HCV infection, which would inﬂuence
to pathogenesis and treatment of chronic hepatitis C.
Methods: We compared results of therapy with pegylated
interferon-alfa plus ribavirin in 79 patients (52%-male) with
HCV. The excessive weight was estimated with body mass index
(BMI). Patients were divided into 3 groups: 1st group with BMI <
25 kg/m2 (27), 2nd group with BMI - 26-30 kg/m 2 (30), 3rd group
with BMI> 30 kg/m2 (22).
Result: After antiviral therapy 59 patients (74,6%) had achieved
sustained virologic response SVR - 68,5% in genotype 1 (37 pa-
tients) and 88% in genotypes 2 and 3 (22). In the third group
(BMI>30 kg/m2) was lowest level of SVR (55,6%). There were high
authentic differences in each group among SVR rate in patients
with and without liver steatosis (p<0.05). Patients without liver
steatosis had SVR in 91% (1st group – 84,2%, 2nd and 3rd groups
– 100%). Patients with steatosis achieved SVR in 45% (1st group
– 37,5%, 2nd group – 70,6% and 3 group – 55,6%). All patients
without liver steatosis in the third group had achieved SVR, on
the other hand just 26.3% patients with steatosis in the same
group had achieved SVR (p<0.05).
Conclusion: The presence of hepatic steatosis is risk factor in
chronic hepatitis C patients. Improvement of the results of an-
tiviral therapy correction concerning liver steatosis is necessary,
both before as well as during the treatment of viral hepatitis
C.
PP-137 The prognostic signiﬁcance of hepatocyte growth
factor activator in liver biopsies of Egyptian
patients with HCV-related chronic hepatitis
Nermine Ehsan1,2, Doha Maher*,1,2, Rehab Samaka2,3,
Hayam Aiad2,3. 1National Liver Institute; 2Menouﬁya University;
3Faculty of Medicine
Background: Hepatocyte growth factor activator (HGFA), is a
pericellular activator of hepatocyte growth factor (HGF) which
plays a potent role in liver repair after injury.
Objectives: The aims of this study were to investigate the im-
munostaining of HGFA in liver tissues from patients with hepatitis
C virus (HCV) infection and to correlate its expression with
the grade of activity, stage of ﬁbrosis and immunohistochemical
expression of transforming growth factor beta1 (TGF-β1).
Methods: Parafﬁn embedded liver sections prepared from 31
biopsies of patients with HCV-related chronic hepatitis (41±8 y)
and 20 normal healthy subjects, donors for liver transplantation
(29±7.5 y) were evaluated for grading and staging of chronic
hepatitis according to Ishak scoring system and applied for im-
munostaining with HGFA and TGF-β1. Semiquantitative analysis
of immunoreactive cells’ intensity and percentage for HGFA and
TGFβ1 were interpreted to calculate the H-score.
Results: Liver tissue from HCV related chronic hepatitis revealed
preferential distribution of HGFA around sites of injury and re-
generation. HGFA H-score correlated signiﬁcantly with the grade
of activity and stage of ﬁbrosis (p<0.01 each) and a highly
statistical signiﬁcant direct correlation between TGF-β1 H-score.
There was a high statistically signiﬁcant difference between nor-
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mal control group and HCV-related chronic hepatitis regarding
the HGFA H-score and TGF-β1 H-score.
Conclusions: Parallel expression of HGFA and TGF-β1 with the
grade of activity and stage of ﬁbrosis in HCV-related chronic hep-
atitis could make HGFA as an activity and regenerative marker.
PP-138 Screening and cloning of gene of hepatocyte
protein interacting with HCV NS5ATP4A protein
Lian-feng Zhang1, Jun Cheng*,2, Li-dong Chen3, Ji-chang Li 1,
Wei Liu. 1The First Afﬁliated Hospital of Zhengzhou University;
2Ditan Hospital, Beijing, China; 3The Second Peoples’ Hospital
of Jiaozuo
Objective: We screen proteins of hepatocyte protein interacting
with hepatitis C virus NS5ATP4A protein to clarify the signal
transduction pathway of HCV.
Methods: “Bait” plasmids of hepatitis C virus NS5ATP4A were
constructed. After verifying that hepatitis C virus NS5ATP4A pro-
tein could be steadily expressed in AH109 yeast strain, yeast-two
hybrid assay was performed by mating AH109 with Y187 that
pre-transformed with liver cDNA library plasmids pACT2, and the
diploidy yeast cells were plated on quadruple dropout (QDO)
medium and assayed for X-α-gal activity. Nineteen yeast colonies
that could grow on QDO and hadα-gal activity were obtained,
then the library plasmids were extracted and sequenced.
Results: 7 genes were screened out and one of them was un-
known gene. These genes were associated RNA synthesis, protein
translation, cell cycle and tumor immune.
Conclusion: NS5ATP4 binding proteins were successfully
screened,which offer new clues to the signal transduction path-
way of NS5ATP4A and the pathogenic mechanism of HCV.
PP-139 The evaluation of the hepatic ﬁbrosis and its
progression rate in chronic hepatitis C
Dana Damian*, Mircea Grigorescu, Teodor Zaharie. Third Medical
Clinic, Cluj Napoca, Romania
Aim: The evaluation of ﬁbrosis through Ishak and Metavir scoring
systems and it’s progression rate.
Methods: We studied 242 naïve patients with chronic hepatitis
C, admitted between 2003 and 2006, who performed liver biopsy
for diagnosis, being evaluated according two scoring systems.
The evaluation of the ﬁbrosis progression rate was performed
only in 55 patients with a previous history of transfusions, using
the ratio between the ﬁbrosis stage and the estimated infection
duration (years).
Results: The mild and moderate ﬁbrosis lesions predominated,
with a concordance between the scoring systems.
The mean ﬁbrosis index was signiﬁcantly larger in patients with
moderate/severe necroinﬂamatory lesions, irrespective of the
normal or increased AST or ALT levels.
The mean ﬁbrosis progression rate of 0.23±0.34 units/year ac-
cording to the Metavir system, and 0.32±0.51 units/year - Ishak
system.
The age at the time of infection and it’s estimated duration
correlate with the Metavir ﬁbrosis progression rate (p =0.000,
respectively p =0.001). The patients who have been infected
before the age of 40 and those with a duration of infection of less
than 20 years have a signiﬁcantly lower mean ﬁbrosis progression
rate.
Conclusions: 1. The mild and moderate ﬁbrosis predominated,
with equivalent results between the two scoring systems.
2. The severity of ﬁbrosis correlated with the age and the
increased AST or ALT levels.
3. The mean ﬁbrosis progression rate was 0.23±0.34 units/year in
the Metavir system, respectively 0.31±0.51 units/year in Ishak,
being correlated with the age at the moment of infection and it’s
estimated duration of evolution.
PP-140 The occult HCV infection
Dana Damian*, Mircea Grigorescu, Mircea Dan Grigorescu,
Teodor Zaharie. Third Medical Clinic, Cluj Napoca, Romania
Aim: evaluating the presence and localisation of the HCV anti-
gens (NS3, NS5, NS5A) in patients with chronic hepatitis C and
undetectable versus detectable serum HCV-RNA.
Methods: 93 patients with chronic hepatitis C were included in
the study, 55 with detectable viremia. Using immunohistochem-
ical techniques involving monoclonal and policlonal antibodies,
we analysed the presence, localisation and semiquantitative
grading of coloured cells.
Results: All untreated patients with detectable viremia pre-
sented hepatocyte expression of viral proteins, especially in the
hepatocyte cytoplasm and less in the nucleus. The untreated sub-
jects with undetectable viremia had similar detection rate as the
untreated patients with detectable viremia, 92.3% respectively
92.4% and 84.61% for NS3, NS5, NS5A.
In treated patients with undetectable viremia, the proportion
of positive results were comparable for NS3 (92%) but lower
for NS5 and NS5A (80% and 60%). The positive immunohisto-
chemical reaction was observed in fewer hepatocytes (< 30%),
with focal lobular distribution and mild/moderate intensity in
treated subjects with undetectable viremia, respectively moder-
ate/important in the rest of patients.
The patients with undetectable viremia were found to have cor-
relationships between the presence of NS3 and NS5 antigens and
the ﬁbrosis level. The presence of steatosis correlated with NS3
and NS5 only in untreated patients with undetectable viremia.
The portal space involvement was observed especially at
macrophages.
Conclusions: Identifying the presence of viral antigens in the
liver tissue in patients with undetectable viremia, who have
either received antiviral therapy or not, can bring into discussion
the occult HCV infection.
PP-141 Predicting treatment response in hepatitis C virus
infected patients: from gene to protein
expression
Limin Chen*,1, Jing Sun1, Maha Guindi 2, Jordan Feld1,
Jenny Heathcote1, Aled Edwards1, Ian McGilvray1. 1Uiversity of
Toronto, Toronto, Canada; 2University Health Network, Toronto,
Canada
Objectives: Chronic hepatitis C virus (CHC) infection is treated
with interferon/ribavirin, but only a subset of patients re-
spond. We previously reported that treatment nonresponders
have marked pre-treatment upregulation of a subset of inter-
feron stimulated genes (ISGs) in their livers, including ISG15
(Chen, et al. Gastroenterology 2005). Here, we study the source
of the ISG expression signature and uncover the cellular basis of
the phenotype through ISG15 and MxA protein expression.
Methods: ISG15 and MxA immunohistochemistry was performed
on a subset of 31 liver biopsies and the expression pattern was
correlated with response status.
Results: Using a simple histology scale scored from 0 to 3
(0: no staining in any cell, 3: staining in every cell), we
found signiﬁcantly more hepatocyte ISG15 expression in treat-
ment non-responders versus responders (2.4±0.6 vs 1.1±0.6,
p<0.0001), but less macrophage ISG15 staining (0.2±0.4 vs
0.8±0.6, p<0.005). MxA protein expression had a similar cell-
speciﬁc pattern of expression. Treatment response was linked
to cell-speciﬁc activation patterns: ISG15 and MxA protein up-
regulation was more pronounced in hepatocytes in treatment
nonresponders, but in Kuppfer cells in responders.
Conclusions: Our previously deﬁned differential gene expression
pattern in the livers of HCV responders and nonresponders is
driven by activation of different cell types: hepatocytes in treat-
ment nonresponders, and macrophages in treatment responders.
